2. Sarilumab in relapsing polymyalgia rheumatica: patient-reported outcomes from a phase 3, double-blind, randomised controlled trial.
作者: Vibeke Strand.;Jerome Msihid.;Jennifer Sloane.;Michael C Nivens.;Jingdong Chao.;Angeliki Giannelou.;Stefano Fiore.;Lita Araujo.;Bhaskar Dasgupta.
来源: Lancet Rheumatol. 2025年
Sarilumab is approved for adult patients with polymyalgia rheumatica who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. We aimed to evaluate the effect of sarilumab on patient-reported outcomes.
4. Immunometabolism in systemic lupus erythematosus.
Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by chronic inflammation, tissue damage, accelerated cardiovascular disease and the synthesis of autoantibodies that target nucleic acids and nuclear protein complexes. Emerging evidence underscores the key role of immune metabolic dysregulation in SLE, revealing how metabolic reprogramming during immune cell activation influences disease development and progression. Alterations in key metabolic pathways such as glycolysis and oxidative phosphorylation profoundly affect the activation, differentiation and function of B and T cells, monocytes, neutrophils and other immune cells, driving inflammation and tissue injury. This Review synthesizes current findings on immune cell metabolism in animal models of lupus and in patients with SLE, highlighting the interplay of metabolic disturbances, mitochondrial dysfunction and disease pathogenesis. Furthermore, it explores the potential of targeting metabolic pathways as therapeutic strategies to mitigate organ damage and improve outcomes in SLE.
5. Comparison of findings on contrast-enhanced MRI of the hand, wrist, and forefoot in healthy controls, two at-risk groups, and patients with rheumatoid arthritis: a cohort study.
作者: Dennis A Ton.;Nikolet K den Hollander.;Hanna W van Steenbergen.;Annette H M van der Helm-van Mil.
来源: Lancet Rheumatol. 2025年
The sensitivity of MRI in detecting joint inflammation in rheumatoid arthritis is well known but its specificity is less discussed. It is important to prevent false positive results and consequent overdiagnosis. Therefore, we aimed to examine MRI-detected inflammation that is less specific for rheumatoid arthritis by evaluating the frequencies of inflammation in healthy controls and in two at-risk groups who have not developed rheumatoid arthritis, compared with patients with rheumatoid arthritis.
8. Serum cytokine levels towards precision medicine in Still's disease: a subanalysis of a randomized controlled trial of tocilizumab.
作者: Koji Suzuki.;Hideto Kameda.;Kei Ikeda.;Tomonori Ishii.;Kosaku Murakami.;Hyota Takamatsu.;Yoshiya Tanaka.;Takayuki Abe.;Tsutomu Takeuchi.;Yuko Kaneko.
来源: Rheumatology (Oxford). 2025年
To predict the efficacy of IL-6 inhibition in patients with Still's disease by analysing inflammatory cytokine profiles before and during an IL-6 receptor inhibitor therapy.
10. Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial.
作者: Maciej Wieczorek.;Bartłomiej Kisiel.;Dorota Włodarczyk.;Piotr Leszczyński.;Iryna V Kurylchyk.;Ivan Vyshnyvetskyy.;Izabela Kierzkowska.;Piotr Pankiewicz.;Michał Kaza.;Martyna Banach.;Joanna Kogut.
来源: Lancet Rheumatol. 2025年
Janus kinase (JAK) inhibitors are an effective treatment option in rheumatoid arthritis and other autoimmune diseases. However, the use of JAK inhibitors is associated with increased total cholesterol, LDL cholesterol, triglycerides, and creatinine kinase, reducing the net clinical benefit of using them. Adding Rho-associated protein kinase (ROCK) inhibition to JAK inhibition might provide cardioprotection as ROCK inhibitors have been shown to reduce vascular inflammation, improve endothelial function, and prevent cardiac remodelling in preclinical models. In this study we investigated CPL409116 (hereafter referred to as CPL'116), a novel dual JAK and ROCK inhibitor, in patients with rheumatoid arthritis with inadequate response to methotrexate, to assess dose-dependent effects on disease control, pharmacokinetics, and laboratory abnormalities among other safety events.
11. Exposure to hydroxychloroquine in early pregnancy and incidence of pre-eclampsia and pre-term delivery in patients with systemic lupus erythematosus in Sweden: a nationwide population-based cohort study.
作者: Ngoc V Nguyen.;Anna Sandström.;Elisabet Svenungsson.;Annica Dominicus.;Elizabeth V Arkema.;Julia F Simard.
来源: Lancet Rheumatol. 2025年
Pregnant women with systemic lupus erythematosus (SLE) have elevated risks of pre-eclampsia and pre-term delivery. Hydroxychloroquine, the mainstay treatment during pregnancy in women with SLE, is currently a promising agent for pre-eclampsia prevention. We aimed to examine associations between hydroxychloroquine use and pre-eclampsia and pre-term delivery in pregnant women with SLE.
14. Patients' experiences of managing their rare rheumatic disease.
作者: Emma Dures.;Celia Almeida.;Sadia Janjua.;Andrew Hunt.;Jen Orme.;Peter C Lanyon.;Nicola Walsh.;Joanna C Robson.
来源: Rheumatology (Oxford). 2025年
The rare autoimmune rheumatic diseases (RAIRDs) include systemic lupus erythematosus (lupus), systemic vasculitis, inflammatory myositis, systemic sclerosis, and Sjögren's Disease. The objective of the study is to understand patients' experiences of living with and managing their RAIRD.
15. Anti-HMGCR myopathy: observed ethnic differences in disease and disease outcomes in New Zealand.
Anti-HMGCR myopathy is an immune-mediated necrotizing myopathy strongly associated with statin use in adults. Polynesians have a higher incidence of anti-HMGCR myopathy in New Zealand (NZ), but ethnic differences in phenotype and outcome are not known.
17. Whole-body MRI in patients with arthralgia or inflammatory arthritis after exposure to immune checkpoint inhibitors: a single-centre prospective imaging study.
作者: Kate Harnden.;Navkiran Sidhu.;Emma Rowbotham.;Laurence Duquenne.;Sana Sharrack.;Keith Howell.;Dominic Bertham.;Kerem Abacar.;Paul Emery.;Dennis McGonagle.;Kulveer Mankia.
来源: Lancet Rheumatol. 2025年
Musculoskeletal adverse events due to immune checkpoint inhibitors are common and can present clinically as inflammatory arthritis, polymyalgia rheumatica, or arthralgia. The pathoanatomy of musculoskeletal adverse events related to immune checkpoint inhibitors remains undefined, with a paucity of available imaging data. We aimed to investigate the whole-body imaging phenotype of arthralgia and inflammatory arthritis following exposure to immune checkpoint inhibitors, to fully characterise the pattern of inflammation in these patients and subsequently inform clinical management.
18. Occupational therapist-led versus rheumatologist-led care in people with hand osteoarthritis in Norway: an open-label, multicentre, randomised controlled, non-inferiority trial.
作者: Annikka Polster.;Unni Olsen.;Lars Asphaug.;Kjetil Bergsmark.;Barbara Christensen.;Ida K Haugen.;Toril Hennig.;Merete Hermann-Eriksen.;Åshild Hove.;Trine Sjøvold.;Joe Sexton.;Anne Therese Tveter.;Ingvild Kjeken.
来源: Lancet Rheumatol. 2025年
Hand osteoarthritis is a common musculoskeletal disease with a rising prevalence due to increased life expectancy. Because the disease is diagnosed on the basis of clinical examination and the first choice of treatment is non-pharmacological, it is not a high-risk condition. We aimed to assess the non-inferiority and cost-effectiveness of occupational therapist-led care for hand osteoarthritis compared with rheumatologist-led care.
20. Re-evaluation of MEFV carriers previously diagnosed with familial Mediterranean fever: a colchicine discontinuation study.
作者: Veysel Cam.;Dilara Unal.;Erdal Sag.;Yagmur Bayindir.;Emil Aliyev.;Hulya Ercan Emreol.;Mehmet Orhan Erkan.;Ozlem Necipoglu Banak.;Hazel Delal Dara Kar.;Ozge Basaran.;Yelda Bilginer.;Seza Ozen.
来源: Rheumatology (Oxford). 2025年
Familial Mediterranean Fever (FMF) is an autoinflammatory disease associated with mutations in the MEFV gene. While typically inherited in an autosomal recessive pattern, heterozygous individuals may also exhibit FMF symptoms, often with a milder disease course. The long-term management of colchicine therapy in heterozygous patients, particularly decisions regarding its discontinuation, remains a clinical challenge.
|